Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.67 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.67 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.67 |
| ▸ | PGR | P06401 | 1/20 | 0.67 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.67 |
| ▸ | HTR2B | P41595 | 1/20 | 0.67 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.67 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.41 |
| ▸ | ECE1 | P42892 | 1/20 | 0.37 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.37 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.36 |
| ▸ | MME | P08473 | 2/20 | 0.36 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.33 |
| ▸ | LAP3 | P28838 | 2/20 | 0.33 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL664076 | 1.00 | CACNA2D1 (0.67) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL664074 | 1.00 | CACNA2D1 (0.67) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL8829767 | 1.00 | CACNA2D1 (0.67) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL9105209 | 0.91 | CACNA2D1 (0.52) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL1410027 | 0.89 | CACNA2D1 (0.74) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| Benzene SCHEMBL27913108 | 0.88 | CACNA2D1 (0.58) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL4659755 | 0.86 | CACNA2D1 (0.52) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| Ethyl Acetate SCHEMBL28029630 | 0.85 | CACNA2D1 (0.50) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL4412290 | 0.84 | CACNA2D1 (0.74) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL12575347 | 0.83 | CACNA2D1 (0.62) | CACNA2D1CACNB3CACNA1CPGRADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 486 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132100-A1 | Method for Purifying Pregabalin | ZHEJIANG HUAHAI PHARMACEUTICAL CO LTD (CN) | 2026-05-14 | — | — | US | claimed |
| CN-122012475-A | Amide hydrolase mutant, biological material, screening method, catalyst and application | 南京大学 | 2026-05-12 | — | — | CN | claimed |
| CN-116515800-B | PaDP protein and application of mutant thereof in enzymatic synthesis of pregabalin chiral intermediate | 中国科学院微生物研究所 | 2025-06-17 | — | — | CN | claimed |
| CN-119979516-A | Dihydropyrimidinase mutant and application thereof in production of (R) -3- (carbamoylmethyl) -5-methylhexanoic acid | 上海奥萝拉医药科技有限公司 | 2025-05-13 | — | — | CN | claimed |
| CN-119955872-A | Synthetic protein of R- (-) -3- (carbamoylmethyl) -5-methylhexanoic acid, mutant and application thereof | 中国科学院微生物研究所 | 2025-05-09 | — | — | CN | claimed |
| CN-119570777-A | Preparation and application of immobilized hydantoin enzyme | 宁波酶赛生物工程有限公司 | 2025-03-07 | — | — | CN | claimed |
| US-20250043323-A1 | BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF PREGABALIN INTERMEDIATES | Enzymaster (Ningbo) Bio-Engineering Co., Ltd (CN) | 2025-02-06 | — | — | US | claimed |
| CN-114164198-B | (R) - (-) -3- (carbamoylmethyl) -5-methylhexanoic acid synthetic protein, mutant and application thereof | 中国科学院微生物研究所 | 2025-01-07 | — | — | CN | claimed |
| CN-109761838-B | Method for preparing pregabalin intermediate and recovering resolving agent | 浙江华海药业股份有限公司 | 2024-12-31 | — | — | CN | claimed |
| EP-4433602-A1 | BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF PREGABALIN INTERMEDIATES | Enzymaster (Ningbo) Bio-Engineering Co., Ltd. (CN) | 2024-09-25 | — | — | EP | claimed |
| US-7462738-B2 | Processes for the preparation of R-(+)-3-(carbamoyl methyl)-5-methylhexanoic acid and salts thereof | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-12-09 | — | — | US | claimed |
| WO-2008137512-A2 | PROCESS FOR PREPARING PREGABALIN VIA HOFMANN REACTION AND CRYSTALLINE FORM THEREOF | DR. REDDY'S LABORATORIES LTD. (IN) | 2008-11-13 | — | — | WO | claimed |
| WO-2008004044-A1 | PROCESS FOR THE PREPARATION OF (R)-(-)-3-(CARBAMOYLMETHYL)-5-METHYLHEXANOIC ACID AND OF PREGABALIN AND SYNTHESIS INTERMEDIATES | LABORATORIO CHIMICO INTERNAZIONALE S.P.A. (IT) | 2008-01-10 | — | — | WO | claimed |
| US-20070293694-A1 | Processes for the preparation of R-(+)-3-(carbamoyl methyl)-5-methylhexanoic acid and salts thereof | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2007-12-20 | — | — | US | claimed |
| WO-2007139933-A2 | PROCESSES FOR THE PREPARATION OF R-(+)-3-(CARBAMOYL METHYL)-5-METHYLHEXANOIC ACID AND SALTS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-12-06 | — | — | WO | claimed |
| EP-0828704-B1 | METHODS OF MAKING (S)-3-(AMINOMETHYL)-5-METHYLHEXANOIC ACID | WARNER LAMBERT CO (US) | 2002-03-13 | — | — | EP | claimed |
| EP-0828704-A1 | METHODS OF MAKING (S)-3-(AMINOMETHYL)-5-METHYLHEXANOIC ACID | WARNER-LAMBERT COMPANY (US) | 1998-03-18 | — | — | EP | claimed |
| US-5629447-A | Methods of making (S)-3-(aminomethyl)-5-methylhexanoic acid | WARNER-LAMBERT COMPANY (US) | 1997-05-13 | — | — | US | claimed |
| US-5616793-A | Methods of making (S)-3-(aminomethyl)-5-methylhexanoic acid | WARNER-LAMBERT COMPANY (US) | 1997-04-01 | — | — | US | claimed |
| WO-1996038405-A1 | METHODS OF MAKING (S)-3-(AMINOMETHYL)-5-METHYLHEXANOIC ACID | WARNER-LAMBERT COMPANY (US) | 1996-12-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132100-A1 | Method for Purifying Pregabalin | CACNG7, CACNG5, GABRB1 | CACNA2D1 36/4885CACNB3 55/4885CACNA1C 6/4885 |
| US-20070293694-A1 | Processes for the preparation of R-(+)-3-(carbamoyl methyl)-5-methylhexanoic acid and salts thereof | RIMKLA, GABRE, GRIK5 | CACNA2D1 245/4885CACNB3 63/4885CACNA1C 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.